▲ Peaking
Business
🔮 holds ✗
Fierce Biotech
Coverage by Fierce Biotech as tracked by Newsylist.
152trends covered
65broke first
153articles tracked
▲ Peaking
Business
🔮 holds ✗
Sanofi scraps STAT6 degrader from Nurix just 2 months after entering clinic
↑ Rising
Business
🔮 holds ✗
Servier’s $1.5B bet on Edgewise drug fails five months in
↓ Cooling
Business
🔮 holds ✗
Ultragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027—Ultragenyx Pharmaceutical Inc.
◼ Archived
Business
🔮 holds ✗
Philips reaches DOJ agreement over device recall, books €288 million provision in Q3
◼ Archived
Business
🔮 holds ✗
Genmab Stock Surges to Record High as Cancer Drug Slashes Risk of Death by 50%
◼ Archived
Business
🔮 fades ✓
Bye bye Ozempic: Eli Lilly says its new drug retatrutide more than doubles weight loss
◼ Archived
Business
🔮 holds ✗
FDA offers new details on quicker approval pathway for personalized gene therapies
◼ Archived
Business
🔮 holds ✗
Novartis CEO keeps faith in Avidity deal despite taking $1.9B hit from del-desiran fail
◼ Archived
Business
🔮 fades ✓
Exclusive | GSK Sees Cancer-Drug Pipeline Nearly Doubling Next Year After Dealmaking Spree
◼ Archived
Business
🔮 holds ✗
Incyte pancreatic cancer medicine induces lasting tumor responses, company says at ESMO
◼ Archived
Business
🔮 fades ✓
Roche Targets Emerging Oncology Market With New Lung-Cancer Drug
◼ Archived
Business
🔮 fades ✓
AstraZeneca Readies New Portfolio of Targeted Cancer Therapies
◼ Archived
Business
🔮 holds ✗
Moderna’s Cancer Vaccine Success Doesn’t Live Up to Early Hype
◼ Archived
Business
🔮 fades ✓
First-of-Its-Kind Vaccine Ushers in New Hope for Cancer Patients
◼ Archived
Business
🔮 holds ✗
Biotech investment is the new front in the U.S.-China trade fight
◼ Archived
Business
🔮 fades ✓
Laboratory operator Quest reports cyber breach affecting patient records
◼ Archived
Business
🔮 holds ✗
Roche builds blockbuster BTK case for fenebrutinib in multiple sclerosis as FDA decision approaches
◼ Archived
Business
🔮 holds ✗
Gilead’s IBD drug eliminated symptoms for patients, mid-stage study finds
◼ Archived
Business
🔮 holds ✗
Silence Therapeutics Enters into Agreement to be Acquired by Merck KGaA, Darmstadt, Germany
◼ Archived
Business
🔮 holds ✗
AbbVie’s next-gen Crohn’s disease combo beats Skyrizi in phase 2 trial
◼ Archived
Business
🔮 holds ✗
Roche returns to China’s Hansoh for $15B biobucks ADC pact
◼ Archived
Business
🔮 holds ✗
China mulls new tech export bans covering AI, biotechnology and solar power
◼ Archived
Business
🔮 holds ✗
Vir CEO sees ‘opportunity to do more deals’ after striking $1.9B Gilead pact for dual-masked TCEs
◼ Archived
Business
🔮 holds ✗
Verastem CEO claims RAS drug has 'set a new benchmark' for tricky cancer in early readout
◼ Archived
Business
🔮 holds ✗
Roche inks $1.2B deal with China's Rona to enter emerging ALK7 obesity race
◼ Archived
Business
🔮 holds ✗
BioNTech’s mRNA cancer vaccine fails phase 3 test, significantly denting analysts’ confidence
◼ Archived
Business
🔮 holds ✗
After $10.9B exit to AbbVie, Apogee execs join Paragon to scale its R&D, company creation engine
◼ Archived
Business
🔮 holds ✗
BMS doubles up with pivotal wins in lung disease, solid tumor that offer hope for post-patent cliff growth
◼ Archived
Business
🔮 fades ✓
Exclusive: AI startup Chai lands GSK deal, its sixth pharma partner in nine months
◼ Archived
Business
🔮 holds ✗
Argenx digests phase 2 celiac win for $2.2B drug, preps pivotal run
◼ Archived
Health
🔮 holds ✗
Cerevance rescues its Parkinson's drug with phase 3 win
◼ Archived
Health
🔮 fades ✓
Experimental vaccine shows promise against deadly brain cancer in some patients
◼ Archived
Business
🔮 fades ✓
Caribou Biosciences, biotech co-founded by Jennifer Doudna, is shutting down
◼ Archived
Health
🔮 holds ✗
Biotech’s peptide shows promise as ‘bait molecule’ to treat neuropathic pain in mice
◼ Archived
Business
🔮 holds ✗
Astra Doesn’t Need a Deal for Growth Beyond 2030, CEO Says
◼ Archived
Business
🔮 holds ✗
CSL pays $355M to co-develop Alentis’ phase 2-stage fibrosis drug
◼ Archived
Business
🔮 holds ✗
Genmab’s latest phase 2 data spur claim ADC is ‘clearly superior’ to AbbVie’s Elahere
◼ Archived
Business
🔮 fades ✓
Genentech pays Alector $100M for preclinical Parkinson’s prospect
◼ Archived
Business
🔮 holds ✗
Introducing Fierce Biotech's 2026 Fierce 15
◼ Archived
Business
🔮 holds ✗
Novartis pens $7.8B deal for Abogen's in vivo autoimmune T-cell engager
◼ Archived
Business
🔮 holds ✗
Sanofi pays Dupixent partner Regeneron $1B upfront for 4 early-stage assets to ignite R&D
◼ Archived
Business
🔮 holds ✗
Beam sues YolTech and Serapha Bio for allegedly stealing its gene editing tech
◼ Archived
Business
🔮 fades ✓
Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
◼ Archived
Business
🔮 holds ✗
People with Type 2 diabetes lost up to 60 pounds on Lilly’s latest weight loss drug
◼ Archived
Business
🔮 fades ✓
UniQure’s gene therapy continues to slow Huntington’s progression after four years
◼ Archived
Science
🔮 holds ✗
NIH details $170 million biomedical research reproducibility effort
◼ Archived
Business
🔮 holds ✗
Merck licenses a KRAS G12D inhibitor for $400M upfront
◼ Archived
Business
🔮 holds ✗
Adicet Bio CAR-T sparks lupus remissions in early trial as ‘new era’ of autoimmune treatment approaches
◼ Archived
Business
🔮 fades ✓
Roche Halts Development of Obesity Drug Candidate
◼ Archived
Business
🔮 holds ✗
Merck, Daiichi pull lung cancer filing after FDA pushback deals another blow to $4B deal
◼ Archived
Business
🔮 holds ✗
Kodiak Sciences stock soars on positive AMD trial data
◼ Archived
Business
🔮 holds ✗
Novo Nordisk to Pay Up to $1.3 Billion for Nanexa’s Drug Delivery Technology
◼ Archived
Business
🔮 holds ✗
Kyverna ‘resetting conversation’ with 1-year miv-cel data as autoimmune CAR-T peers hit safety snags
◼ Archived
Business
🔮 holds ✗
Merck sees pivotal victory for $3B eye disease prospect
◼ Archived
Business
🔮 holds ✗
Roche Drug Candidate Hits Target in Late-Stage Study for Autoimmune Disease
◼ Archived
Business
🔮 holds ✗
Nvidia-backed Iambic files for IPO, disclosing new clinic and dealmaking details
◼ Archived
Business
🔮 holds ✗
Novartis secures new radioligand in $900M deal as competition strengthens
◼ Archived
Business
🔮 holds ✗
Otsuka heads to FDA as Ionis-partnered ALS drug hits primary phase 3 endpoint
◼ Archived
Business
🔮 holds ✗